Liquid Biopsy Market
Liquid Biopsy Market Forecasts to 2030 - Global Analysis By Product & Services (Kits & Reagents, Platforms & Instruments and Services), By Type of Sample (Blood, Saliva, Urine and Other Types of Samples), Technology (Multi-gene Parallel Analysis using NGS and Single-gene Analysis using PCR Microarrays), Circulating Biomarker, Cancer, Clinical Application, End User and By Geography
Years Covered |
2021-2030 |
Estimated Year Value (2023) |
US $5.1 BN |
Projected Year Value (2030) |
US $18.8 BN |
CAGR (2023-2030) |
20.3% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Liquid Biopsy Market is accounted for $5.1 billion in 2023 and is expected to reach $18.8 billion by 2030 growing at a CAGR of 20.3% during the forecast period. Liquid biopsy is a non-invasive medical test that detects biomarkers, such as circulating tumor DNA (ctDNA), RNA, and proteins, in bodily fluids like blood or urine. It provides insights into a patient's health, particularly in cancer diagnostics, by identifying genetic mutations or alterations associated with the disease. Liquid biopsy offers a less invasive method to monitor and analyze molecular changes, aiding in early detection, treatment response assessment, and personalized medicine. This innovative approach revolutionizes cancer diagnostics and monitoring, offering a dynamic and real-time perspective on an individual's health status.
According to the International Agency for Research on Cancer, the most prevalent types of cancer includes lungs cancer, breast cancer, prostate cancer, and colorectal cancer. The cancer cases across the globe is estimated to rise by 47% from 2020 to 2040, and the number of cancer cases are estimated to be 28.4 million by 2040 across the globe.
Market Dynamics:
Driver:
Increasing prevalence of cancer globally
The escalating global prevalence of cancer serves as a significant driver for the liquid biopsy market. As cancer incidence rises worldwide, there is a growing need for effective and non-invasive diagnostic tools. Liquid biopsies, offering a minimally invasive approach to detecting and monitoring cancers, meet this demand. They enable early detection, treatment customization, and real-time monitoring of therapeutic responses. Moreover, the increasing recognition of liquid biopsies as valuable tools in the fight against cancer positions them as a crucial component in addressing the rising burden of this disease on a global scale.
Restraint:
Sensitivity and specificity challenges
The variable performance of these tests in terms of accurately detecting and ruling out specific conditions raises concerns about their reliability. Achieving high sensitivity is crucial for clinical utility. Inconsistent results may lead to false positives or negatives, impacting the overall accuracy of liquid biopsy and thereby hindering overall market growth.
Opportunity:
Government investments on healthcare infrastructure
Increased funding enhances research and development, aiding technological advancements and innovation in liquid biopsy technologies. Improved infrastructure fosters better accessibility to diagnostic services, promoting the adoption of liquid biopsy for early cancer detection. Government support can also facilitate the integration of liquid biopsy into mainstream healthcare systems, ensuring widespread availability. This aligns with public health initiatives, creating a conducive environment for market growth.
Threat:
Stringent regulatory requirements and competition with traditional biopsy methods
Stringent regulatory requirements pose a threat to the liquid biopsy market by potentially slowing down product approvals and market entry. Meeting these requirements demands substantial resources and time. Additionally, the market faces competition from well-established traditional biopsy methods, leading to skepticism and slower adoption. Physicians and healthcare institutions may prefer conventional approaches they are familiar with, hindering the rapid integration of liquid biopsy techniques.
Covid-19 Impact:
The COVID-19 pandemic had a significant effect on the liquid biopsy market. Disruptions in healthcare systems and priorities diverted attention and resources away from non-essential diagnostics, slowing market growth. However, the pandemic underscored the importance of non-invasive and remote diagnostics, fueling interest in liquid biopsy technologies. The need for minimizing patient contact and expediting diagnostic processes accelerated the adoption of liquid biopsies, especially in oncology, demonstrating their potential resilience and adaptability in response to healthcare challenges posed by the pandemic.
The blood segment is expected to be the largest during the forecast period
Over the forecast period, the blood segment is poised to dominate the liquid biopsy market, securing the largest market share. This dominance is attributed to the escalating demand for non-invasive cancer diagnostics and the convenience of obtaining blood samples. Blood-based liquid biopsies, leveraging circulating tumor DNA (ctDNA) and other biomarkers, facilitate early cancer detection and treatment monitoring. Additionally, the segment's growth is further propelled by advancements in high-throughput technologies like next-generation sequencing, which enhance the precision of molecular analysis.
The prostate cancer segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the prostate cancer segment is expected to witness unparalleled growth in the liquid biopsy market. This surge is driven by the pressing need for accurate and minimally invasive diagnostic solutions for prostate cancer, a prevalent and often asymptomatic condition. Liquid biopsy's ability to detect circulating tumor DNA (ctDNA) and other biomarkers from a simple blood draw offers a revolutionary approach to prostate cancer diagnosis and monitoring. Moreover, advancements in liquid biopsy technologies, coupled with a growing emphasis on personalized medicine, position the prostate cancer segment at the forefront of the market's expansion.
Region with largest share:
North America is anticipated to command the largest market share during the forecast period in the liquid biopsy market. This dominance is attributed to factors such as a well-established healthcare infrastructure, increased investment in research and development, and a high prevalence of cancer. Moreover, the region benefits from the early adoption of advanced medical technologies and a strong emphasis on personalized medicine. Additionally, the presence of key market players, coupled with favorable government initiatives, positions North America at the forefront of the liquid biopsy market.
Region with highest CAGR:
The Asia Pacific region is positioned to experience the highest CAGR during the forecast period in the liquid biopsy market. Owing to the rising incidence of cancer, improving healthcare infrastructure, and increasing adoption of advanced diagnostic technologies. The region's large and diverse population, coupled with government initiatives to enhance healthcare services, fosters the demand for non-invasive cancer diagnostics. Additionally, collaborations between international and local companies, along with a growing focus on precision medicine, further drive the expansion of the liquid biopsy market in the Asia Pacific region.
Key players in the market
Some of the key players in Liquid Biopsy Market include ANGLE plc, Biocept Inc., Bio-Rad Laboratories, Epigenomics AG, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., RareCyte, Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Laboratory Corporation of America Holdings, Lucence Health Inc., MDxHealth SA, Myriad Genetics, Inc., Oncimmune, QIAGEN N.V and Thermo Fisher Scientific Inc.
Key Developments:
In November 2023, ANGLE plc, a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the launch of its Portrait® PD-L1 test for the evaluation of PD-L1 protein expression on CTCs following extensive development and optimisation. The test is provided as a service from ANGLE's Onc-ADaPT® GCP-compliant laboratories and is conducted by an expert team with over 10 years' experience in CTC analysis.
In March 2023, ANGLE plc, a world-leading liquid biopsy company, is delighted to announce that its first bespoke assay development customer, Artios Pharma (Artios), has signed a new contract to utilise two DNA Damage Response assays developed by ANGLE in a Phase 1 clinical trial expected to commence short.
Product & Services Covered:
• Kits & Reagents
• Platforms & Instruments
• Services
Type of Samples Covered:
• Blood
• Saliva
• Urine
• Other Types of Samples
Technologies Covered:
• Multi-gene Parallel Analysis using NGS
• Single-gene Analysis using PCR Microarrays
Circulating Biomarkers Covered:
• Cell-free DNA (cfDNA)
• Circulating Tumor Cells
• Circulating Tumor DNA (ctDNA)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers
Cancers Covered:
• Breast Cancer
• Colorectal Cancer
• Liver Cancer
• Lung Cancer
• Prostate Cancer
• Other Cancers
Clinical Applications Covered:
• Early Cancer Screening
• Recurrence Monitoring
• Therapy Selection
• Treatment Monitoring
• Other Clinical Applications
End Users Covered:
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Hospitals and Clinics
• Pharmaceutical and Biotechnology Companies
• Research Institutions
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Liquid Biopsy Market, By Product & Services
5.1 Introduction
5.2 Kits & Reagents
5.3 Platforms & Instruments
5.4 Services
6 Global Liquid Biopsy Market, By Type of Sample
6.1 Introduction
6.2 Blood
6.3 Saliva
6.4 Urine
6.5 Other Types of Samples
7 Global Liquid Biopsy Market, By Technology
7.1 Introduction
7.2 Multi-gene Parallel Analysis using NGS
7.3 Single-gene Analysis using PCR Microarrays
8 Global Liquid Biopsy Market, By Circulating Biomarker
8.1 Introduction
8.2 Cell-free DNA (cfDNA)
8.3 Circulating Tumor Cells
8.4 Circulating Tumor DNA (ctDNA)
8.5 Extracellular Vesicles (EVS)
8.6 Other Circulating Biomarkers
9 Global Liquid Biopsy Market, By Cancer
9.1 Introduction
9.2 Breast Cancer
9.3 Colorectal Cancer
9.4 Liver Cancer
9.5 Lung Cancer
9.6 Prostate Cancer
9.7 Other Cancers
10 Global Liquid Biopsy Market, By Clinical Application
10.1 Introduction
10.2 Early Cancer Screening
10.3 Recurrence Monitoring
10.4 Therapy Selection
10.5 Treatment Monitoring
10.6 Other Clinical Applications
11 Global Liquid Biopsy Market, By End User
11.1 Introduction
11.2 Ambulatory Surgical Centers
11.3 Diagnostic Laboratories
11.4 Hospitals and Clinics
11.5 Pharmaceutical and Biotechnology Companies
11.6 Research Institutions
11.7 Other End Users
10 Global Liquid Biopsy Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 ANGLE plc
12.2 Biocept Inc.
12.3 Bio-Rad Laboratories
12.4 Epigenomics AG
12.5 F. Hoffmann-La Roche Ltd.
12.6 Freenome Holdings, Inc.
12.7 RareCyte, Inc.
12.8 Guardant Health, Inc.
12.9 Illumina, Inc.
12.10 Johnson & Johnson
12.11 Laboratory Corporation of America Holdings
12.12 Lucence Health Inc.
12.13 MDxHealth SA
12.14 Myriad Genetics, Inc.
12.15 Oncimmune
12.16 QIAGEN N.V
12.17 Thermo Fisher Scientific Inc
List of Tables
1 Global Liquid Biopsy Market Outlook, By Region (2021-2030) ($MN)
2 Global Liquid Biopsy Market Outlook, By Product & Services (2021-2030) ($MN)
3 Global Liquid Biopsy Market Outlook, By Kits & Reagents (2021-2030) ($MN)
4 Global Liquid Biopsy Market Outlook, By Platforms & Instruments (2021-2030) ($MN)
5 Global Liquid Biopsy Market Outlook, By Services (2021-2030) ($MN)
6 Global Liquid Biopsy Market Outlook, By Type of Sample (2021-2030) ($MN)
7 Global Liquid Biopsy Market Outlook, By Blood (2021-2030) ($MN)
8 Global Liquid Biopsy Market Outlook, By Saliva (2021-2030) ($MN)
9 Global Liquid Biopsy Market Outlook, By Urine (2021-2030) ($MN)
10 Global Liquid Biopsy Market Outlook, By Other Types of Samples (2021-2030) ($MN)
11 Global Liquid Biopsy Market Outlook, By Technology (2021-2030) ($MN)
12 Global Liquid Biopsy Market Outlook, By Multi-gene Parallel Analysis using NGS (2021-2030) ($MN)
13 Global Liquid Biopsy Market Outlook, By Single-gene Analysis using PCR Microarrays (2021-2030) ($MN)
14 Global Liquid Biopsy Market Outlook, By Circulating Biomarker (2021-2030) ($MN)
15 Global Liquid Biopsy Market Outlook, By Cell-free DNA (cfDNA) (2021-2030) ($MN)
16 Global Liquid Biopsy Market Outlook, By Circulating Tumor Cells (2021-2030) ($MN)
17 Global Liquid Biopsy Market Outlook, By Circulating Tumor DNA (ctDNA) (2021-2030) ($MN)
18 Global Liquid Biopsy Market Outlook, By Extracellular Vesicles (EVS) (2021-2030) ($MN)
19 Global Liquid Biopsy Market Outlook, By Other Circulating Biomarkers (2021-2030) ($MN)
20 Global Liquid Biopsy Market Outlook, By Cancer (2021-2030) ($MN)
21 Global Liquid Biopsy Market Outlook, By Breast Cancer (2021-2030) ($MN)
22 Global Liquid Biopsy Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
23 Global Liquid Biopsy Market Outlook, By Liver Cancer (2021-2030) ($MN)
24 Global Liquid Biopsy Market Outlook, By Lung Cancer (2021-2030) ($MN)
25 Global Liquid Biopsy Market Outlook, By Prostate Cancer (2021-2030) ($MN)
26 Global Liquid Biopsy Market Outlook, By Other Cancers (2021-2030) ($MN)
27 Global Liquid Biopsy Market Outlook, By Clinical Application (2021-2030) ($MN)
28 Global Liquid Biopsy Market Outlook, By Early Cancer Screening (2021-2030) ($MN)
29 Global Liquid Biopsy Market Outlook, By Recurrence Monitoring (2021-2030) ($MN)
30 Global Liquid Biopsy Market Outlook, By Therapy Selection (2021-2030) ($MN)
31 Global Liquid Biopsy Market Outlook, By Treatment Monitoring (2021-2030) ($MN)
32 Global Liquid Biopsy Market Outlook, By Other Clinical Applications (2021-2030) ($MN)
33 Global Liquid Biopsy Market Outlook, By End User (2021-2030) ($MN)
34 Global Liquid Biopsy Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
35 Global Liquid Biopsy Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
36 Global Liquid Biopsy Market Outlook, By Hospitals and Clinics (2021-2030) ($MN)
37 Global Liquid Biopsy Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
38 Global Liquid Biopsy Market Outlook, By Research Institutions (2021-2030) ($MN)
39 Global Liquid Biopsy Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.